Immunologia e tumori. Le parole per dirlo
11. Pardoll D. Chapter 6: Cancer immunology. In: Niederhuber JE, Armitage JO, DoroshowJH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th Edition. Philadelphia, Pa: Elsevier, 2014.
16. Joshi S, Kaur S, Redig AJ, et al. Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci U S A 2009; 106 (29): 12097-102.
12. Goldenberg DM, Sharkey RM Novel radiolabeled antibody conjugates. Oncogene 2007; 26 (25): 3734-44.
17. Klein J. Seeds of time: Fifty years ago Peter A. Gorer discovered the H-2 complex. Immunogenetics 1986; 24: 331-8.
13. Rescigno M, Avogadri F, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta 2007; 1776 (1): 108-23.
18. Shinohara T, Taniwaki M, Ishida Y, Kawaichi M, Honjo T. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics 1994; 23 (3): 704-6.
14. Rosenberg SA, Robbins PF, Restifo NP. Chapter 30: Cancer immunotherapy. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles & practice of oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2011.
19. McDermott J, Jimeno A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today (Barc) 2015; 51 (1): 7-20.
15. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012; 104 (8): 599-613.
20. Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol 2015 [Epub ahead of print]. 21. http://www.ema.europa.eu/docs/ it_IT/document_library/EPAR_-_ Product_Information/human/ 000281/WC500034679.pdf
23